Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
主要股東

和黃醫藥共發行871,256,270股普通股。 於納斯達克上市的每股美國存託股份(ADS)相當於五股普通股。

僅作說明:如果轉換所有普通股, 則相當於174,251,254股納斯達克交易的ADS。

就和黃醫藥而言,其已發行股本中約39.90%並非由公眾持有,而是由和黃醫藥的董事、高級行政人員及長江和記實業有限公司持有。長江和記實業有限公司為和黃醫藥主要股東。

和黃醫藥股本中之主要和重大權益的披露受 (i) 英國金融行為監管局(U.K. Financial Conduct Authority)披露指引及透明度規則(Disclosure Rules and Transparency Rules)第5章條文規定(已被納入本公司的組織章程細則);(ii) 美國 1934 年證券交易法的約束;以及 (iii) 香港證券及期貨條例》(香港法律第571章)。

就和黃醫藥所知,持有和黃醫藥已發行股本之3% 或以上的股東及其董事的權益載於下表。

最後更新時間:2023年12月8日

主要股東

股東 持有股份╱擁有權益之股份數目 所佔已發行股本的概約百分比
CK Hutchison Holdings Limited (1) 332,574,650 38.46%
M&G Plc (2) 43,173,457 4.96%
CA Fern Parent (3) 40,847,500 4.69%
 
Notes:
The above table sets out the interests of certain shareholders, insofar as HUTCHMED is aware based on public disclosure as of June 30, 2023. Includes the interests and short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO, or as otherwise notified to the Company and HKEX under Part XV of the SFO. For details of the capacity of each substantial shareholder’s interests, please refer to the “Interests and Short Positions of Shareholders Discloseable under the Securities and Futures Ordinance” section in the 2023 Interim Report. The above table includes Long Positions only – excludes short positions and lending pools.
(1) Please refer to 2023 Interim Report for details. As of July 15, 2021, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on July 19, 2021.
(2) As of November 2, 2023, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on November 3, 2023.  An aggregated 44,433,217 ordinary shares (long position) are held by M&G Plc indirectly through its certain subsidiaries.
(3) CA Fern Parent is wholly owned by several entities which are, by and through their control affiliates (including their respective general partners), ultimately controlled (directly or indirectly) by The Carlyle Group Inc., but The Carlyle Group Inc. has no beneficial interest in the underlying securities of the Company. As of June 30, 2021, notified via disclosure form TR-1 filed on AIM on July 2, 2021.

董事

董事 持有股份╱相關股份數目 所佔已發行股本的概約百分比
蘇慰國 8,162,525 0.94%
鄭澤鋒 2,695,625 0.31%
杜志強 2,466,185 0.28%
施熙德 1,200,000 0.14%
Dan ELDAR 150,660 0.02%
莫樹錦 136,705 0.02%
Paul CARTER 108,925 0.01%
Graeme JACK 86,695 0.01%
楊凌 0 0%
(總計: 15,007,320)  
 
Notes:
As of September 15, 2023.
Includes the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”)) which were notified to the Company and The Stock Exchange of Hong Kong Limited (the “HKEX”) pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors and chief executive of the Company were deemed or taken to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the HKEX pursuant to the Code on Dealings in Shares by Directors adopted by the Company. For details of the capacity and nature of each Director’s interests, please refer to the “Disclosure of Interest” section in the 2023 Interim Report.